Your browser doesn't support javascript.
loading
Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy-An NIAID/AHRQ Workshop.
Wheatley, Lisa M; Wood, Robert; Nadeau, Kari; Liu, Andrew; Zoratti, Edward; Bacharier, Leonard; Brittain, Erica; Calderon, Moises; Casale, Thomas; Chipps, Bradley; Cox, Linda; Creticos, Peter S; Desai, Manisha; Dreborg, Sten; Durham, Stephen; Gergen, Peter J; Gruchalla, Rebecca; Nelson, Harold; O'Hehir, Robyn E; Plaut, Marshall; Schwaninger, Julie M; Tilles, Stephen; Vickery, Brian; Wittenberg, Kim M; Togias, Alkis.
Afiliación
  • Wheatley LM; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md. Electronic address: lisa.wheatley@nih.gov.
  • Wood R; Johns Hopkins University, Baltimore, Md.
  • Nadeau K; Stanford University, Stanford, Calif.
  • Liu A; Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo.
  • Zoratti E; Henry Ford Hospital, Detroit, Mich.
  • Bacharier L; Washington University School of Medicine, St Louis, Mo.
  • Brittain E; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md.
  • Calderon M; Imperial College London, London, United Kingdom.
  • Casale T; University of South Florida, Tampa, Fla.
  • Chipps B; Capital Allergy and Respiratory Disease Center, Sacramento, Calif.
  • Cox L; Nova Southeastern University, Fort Lauderdale, Fla.
  • Creticos PS; Johns Hopkins University School of Medicine, Baltimore, Md.
  • Desai M; Quantitative Sciences Unit, Stanford University, Stanford, Calif.
  • Dreborg S; Uppsala University, Uppsala, Sweden.
  • Durham S; Imperial College London, London, United Kingdom.
  • Gergen PJ; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md.
  • Gruchalla R; University of Texas, Southwestern Medical Center, Dallas, Tex.
  • Nelson H; National Jewish Health, Denver, Colo.
  • O'Hehir RE; Alfred Hospital and Monash University Medical School, Melbourne, Australia.
  • Plaut M; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md.
  • Schwaninger JM; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md.
  • Tilles S; University of Washington, Seattle, Wash.
  • Vickery B; North Carolina Children's Hospital, University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Wittenberg KM; Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, Md.
  • Togias A; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Md.
J Allergy Clin Immunol ; 143(5): 1711-1726, 2019 05.
Article en En | MEDLINE | ID: mdl-30731123
ABSTRACT
The Agency for Healthcare Research and Quality and the National Institute of Allergy and Infectious Diseases organized a workshop to develop trial concepts that could improve the use and effectiveness of aeroallergen immunotherapy (AAIT). Expert groups were formed to accomplish the following tasks (1) propose a study design to compare the effectiveness and safety of subcutaneous versus sublingual AAIT; (2) propose a study design to compare the effectiveness and safety of AAIT by using 1 or a few allergens versus all or most allergens to which a patient is sensitized; (3) propose a study design to determine whether AAIT can alter the progression of childhood allergic airways disease; and (4) propose a study design to determine the optimal dose and duration of AAIT to achieve maximal effectiveness with acceptable safety. Study designs were presented by the workgroups, extensively discussed at the workshop, and revised for this report. The proposed trials would be of long duration and require large highly characterized patient populations. Scientific caveats and feasibility matters are discussed. These concepts are intended to help the development of clinical trials that can address some of the major questions related to the practice of AAIT for the management and prevention of allergic airways disease.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Desensibilización Inmunológica / Hipersensibilidad Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Allergy Clin Immunol Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Asma / Desensibilización Inmunológica / Hipersensibilidad Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Allergy Clin Immunol Año: 2019 Tipo del documento: Article